vTv Therapeutics Inc. (VTVT)
Last updated: 2026-10-21 00:56:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
vTv Therapeutics Inc. (VTVT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $27.83, with a market capitalization of $104.94M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $19.50 to $44.00. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$104.94M | |
$27.47 | |
$560.00 | |
$7.38 | |
$26.94 | |
19.71K | |
61.01K | |
-- | |
$44.00 | |
$19.50 | |
-- | |
-- |
vTv Therapeutics Inc. (VTVT) Latest Closing Stock Price
vTv Therapeutics Inc. (VTVT) last closed at $26.94 as of 2026-10-20 21:01:00, unchanged from the previous close of $26.94.
During the latest regular trading session, VTVT traded between $7.38 and $560.00, with a volume of 19.71K shares. The closing price was near the lower end and near the middle of its 52-week range.
vTv Therapeutics Inc. (VTVT) 7-Day Stock Price Change
Over the past seven days, vTv Therapeutics Inc. (VTVT) moved from $31.18 to $27.83, representing a decline of 10.76% ($3.36).
The stock traded between $25.95 and $31.22 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 20.59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
VTVT 52-Week Price Position
Position in Range: 34.0%
VTVT is currently trading at $27.83, placing it 34.0% of the way from its 52-week low of $19.50 to its 52-week high of $44.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is vTv Therapeutics Inc. (VTVT)?
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
vTv Therapeutics Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
How to Buy vTv Therapeutics Inc. (VTVT) Stock on MEXC
Eligible investors can buy real shares of vTv Therapeutics Inc. (VTVT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is vTv Therapeutics Inc. (VTVT) stock price today?
2.Is VTVT stock going up or down today?
3.What is VTVT pre-market price?
4.What is VTVT after-hours price?
5.Is VTVT stock trading now?
6.Where does VTVT sit relative to its 52-week high and low?
7.What sector is vTv Therapeutics Inc. in?
8.What is vTv Therapeutics Inc.'s market capitalization and where is it listed?
9.How is VTVT valued in terms of P/E ratio and EPS?
10.Does vTv Therapeutics Inc. pay a dividend?
Explore More US Stocks
Search Stocks
VTVT Stock Calculator
Estimate the value between VTVT shares and USD.
VTVT Shares to USD
1.00 VTVT shares = 27.825 USD
Calculations are estimates based on the latest available price and are for reference only.


